We’re building a technologically advanced cannabinoid pharmaceutical company unlike any other

InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.

InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.

InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed’s products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.

InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a spectrum of diseases with high unmet medical need. We intend to accomplish this goal by integrating the central components of our unique drug development business model.

Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.

Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any others.